In this online CME self-learning program:
Systemic lupus erythematosus (SLE) is an autoimmune disease with heterogeneous clinical phenotypes, all with varying degrees of severity. Much like the clinical presentation of SLE, the etiology of SLE is also varied. Although the precise mechanism of SLE-related autoimmunity is still uncertain, strong evidence implicates a combination of genetic and environmental factors in the disease pathology. For most of the medical community, the primary challenges of SLE management stem from the disease heterogeneity, which leads to difficulty in diagnosing, treating, and monitoring.
Early diagnosis is an important component of improving outcomes for patients with SLE, yet many patients experience significant diagnostic delays. When patients are stratified based on the length of diagnostic lag, those with less than 6 months from probable symptom onset to time of diagnosis have fewer flares and hospitalizations compared with those who have more than 6 months of diagnostic delay. Furthermore, patients in the late diagnosis group have significantly higher inpatient costs per month compared with the early diagnosis group ($539 vs $411, respectively, P = 0.001).
Faculty introduction, disclosures
Epidemiology and etiology of SLE.
The importance of early diagnosis.
Treat-to-target in SLE practice
Summary, best practice recap, conclusion
The following HCPs: rheumatologists and primary care physicians; physician assistants, nurse practitioners, nurses, and pharmacists who practice in rheumatology; and any other HCP with an interest in or who clinically encounter patients with SLE.
This program is supported by an educational grant from Mallinckdrodt
Release Date: April 01, 2017 -- Expiration Date: April 01, 2019
Faculty: Sharon Dowell, MD
By the end of the session the participant will be able to:
As a provider of continuing medical education, it is the policy of ScientiaCME to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, faculty and educational planners must disclose any significant relationships with commercial interests whose products or devices may be mentioned in faculty presentations, and any relationships with the commercial supporter of the activity. The intent of this disclosure is to provide the intended audience with information on which they can make their own judgments. Additionally, in the event a conflict of interest (COI) does exist, it is the policy of ScientiaCME to ensure that the COI is resolved in order to ensure the integrity of the CME activity. For this CME activity, any COI has been resolved thru content review ScientiaCME.
Faculty Disclosure: Sharon Dowell, MD, Assistant Professor of Medicine Howard University Hospital, Washington, DC discloses that she received Research grant support from Bristol-Myers Squibb, Pfizer, and Genentech; is a member of the Speaker’s Bureau of Horizon Pharma, and has received funding for Clinical Trials from GlaxoSmithKline.
Disclosures of Educational Planners: Charles Turck, PharmD, BCPS, BCCCP has no relevant conflicts of interest to disclose.
Commercial Support Disclosure: This program is supported by an educational grant from Mallinkdrodt.
*Required to view Printable PDF Version
Please take a few minutes to participate in the optional pre-test. It will help us measure the knowledge gained by participating in this activity.